<DOC>
	<DOCNO>NCT00641160</DOCNO>
	<brief_summary>The purpose study determine safety oral administration vinorelbine daily least 7 day . The study conduct subject non-hematologic malignancy currently accept therapy .</brief_summary>
	<brief_title>Safety Study Oral Vinorelbine Subjects With Non-Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>capable understanding study requirement able provide Informed Consent diagnose nonhematologic malignancy currently accept therapy life expectancy least 3 month agreement use medically acceptable contraception throughout study willing able comply protocol requirement currently receive systemic treatment malignancy yet recover toxicity prior therapy platelet count &lt; 100,000 cells/mm3 within 7 day prior study entry ANC &lt; 1500 cells/mm3 within 7 day prior study entry hemoglobin &lt; 8.5 g/dL within 7 day prior study entry AST and/or ALT &gt; 2.5 X ULN within 7 day prior study entry total bilirubin &gt; 1.5 X ULN within 7 day prior study entry creatinine clearance &lt; 60 mL/min ( CockroftGault formula ) within 7 day prior study entry receipt investigational therapy within 3 week prior study entry know history HIV , HBV , and/or HCV infection clinically relevant active infection serious comorbid medical condition study entry major surgery within 4 week prior study entry malignancy within 3 year prior study entry pregnant breastfeeding presence concomitant disease condition , opinion Investigator , could interfere conduct study could put subject unacceptable risk</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>vinorelbine</keyword>
	<keyword>metronomic dosing</keyword>
	<keyword>oral administration</keyword>
	<keyword>nonhematologic malignancy</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>